Cerecor (CERC) Announces CERC-301 Phase 2 Missed Primary Endpoint in MDD
Tweet Send to a Friend
Cerecor Inc. (Nasdaq: CERC) announced top-line clinical results from its major depressive disorder (MDD) Phase 2 clinical trial (Clin301-203) of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
